

## CLINICAL POLICY ADVISORY GROUP (CPAG)

### Oraya Therapy for the Treatment of Wet Age-related Macular Degeneration (AMD) Position Statement

#### Statement

Derby and Derbyshire CCG (DDCCG) has deemed that Oraya Therapy for the treatment of wet age-related macular degeneration (AMD) should not routinely be commissioned as it falls under [NICE IPG049 Radiotherapy for age-related macular degeneration \(March 2004\)](#).

DDCCG does not fund any procedure or technology assessed by NICE under their IPG unless the provider has submitted a robust, evidenced based business case to the commissioner and this has been subsequently approved. See the [DDCCG IPG Policy](#) for more information.

The CCG's commissioning intentions will be reviewed periodically. This is to ensure affordability against other services commissioned by the CCG.

#### Reference

- Interventional Procedures Guidance Policy, NHS Derby and Derbyshire CCG, updated February 2020, accessed 09/08/21, [http://www.derbyshiremedicinesmanagement.nhs.uk/assets/Clinical-Policies/Clinical\\_Policies/IPG/interventional\\_procedures\\_guidance\\_policy.pdf](http://www.derbyshiremedicinesmanagement.nhs.uk/assets/Clinical-Policies/Clinical_Policies/IPG/interventional_procedures_guidance_policy.pdf)
- Radiotherapy for age-related macular degeneration, NICE interventional procedures guidance [IPG49], published 24/03/04, considered for reassessment January 2011, accessed 09/08/21, <https://www.nice.org.uk/guidance/IPG49>